On February 27th, 2026, The World Health Organization (WHO) announced the recommendations for influenza vaccine composition for the 2026-2027 northern hemisphere season.
For vaccines for use in the 2026-2027 northern hemisphere influenza season, WHO recommends the following:
Egg-based vaccines
- an A/Missouri/11/2025 (H1N1)pdm09-like virus;
- an A/Darwin/1454/2025 (H3N2)-like virus; and
- a B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus.
Cell culture-, recombinant protein- or nucleic acid-based vaccines
- an A/Missouri/11/2025 (H1N1)pdm09-like virus;
- an A/Darwin/1415/2025 (H3N2)-like virus; and
- a B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus.
If you wish to review the WHO recommendations, please click on the link: Recommendations for influenza vaccine composition for the 2026–2027 northern hemisphere season
CSL Seqirus is a central partner to clinicians and pharmacists, providing a range of vaccines to offer their patients and consumers innovative options.
CSL Seqirus work with leading Canadian researchers, healthcare professionals and public health leaders to advance scientific knowledge and global influenza research.
National Recommendations
NACI Seasonal Influenza Vaccine Statement